MAPT and Alzheimer disease: In fact, tau immunotherapy in amyloid precursor protein (APP)-transgenic (tg) mouse models of AD show reduction in not only total tau, but also Aß oligomers, suggesting that targeting tau may have beneficial downstream effects (Castillo-Carranza et al., 2015; Dai et al., 2017; Levenson et al., 2016).